|Bid||161.00 x 800|
|Ask||175.87 x 800|
|Day's range||162.18 - 165.22|
|52-week range||128.58 - 184.00|
|PE ratio (TTM)||23.07|
|Earnings date||5 Nov 2018 - 9 Nov 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||195.00|
Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to begin learning about how toRead More...
Today, the European Commission (or EC) approved the marketing authorization of Jazz Pharmaceuticals’ (JAZZ) Vyxeos. This authorization covers the treatment of adult individuals with newly diagnosed treatment-associated acute myeloid leukemia with myelodysplasia-related changes (or AML-MRC).
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Five top stocks with IBD Composite Ratings of 95 or higher are closing in on buy points: Urban Outfitters, Veeva Systems, Copart, Automatic Data Processing and Jazz Pharmaceuticals.
In its Q2 2018 earnings conference call, Endo International (ENDP) raised its 2018 adjusted EBITDA guidance from $1.2 billion–$1.3 billion to $1.27 billion–$1.33 billion. It expects its adjusted gross margin to be 68.5%–69.5%, which is higher than its previously projected range of 67%–68%. Wall Street analysts have projected Endo International’s 2018 adjusted diluted EPS at $2.50, which would be a YoY decline of 34.4%.
In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY (year-over-year) decline of 18.4%. Additionally, the discontinuation of commercialization of certain generic pharmaceutical products in the US market, competitive pressures, and the divestitures of Grupo Farmacéutico Somar and Litha Healthcare Group had negative impacts on Q2 revenues. To know more about the performance of Endo International stock after its Q2 2018 earnings release, be sure to read Why Endo International Stock Soared after Q2 Results.
In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.
The stock market was mildly lower early Wednesday, as China retaliated with new tariffs on U.S. goods. Michael Kors is breaking out today.
Jazz Pharmaceuticals on Tuesday reported adjusted income of $3.49 per share on sales of $500 million for its second quarter.
How Did Jazz Pharmaceuticals Fare in the Second Quarter? Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $356.0 million in the second quarter of 2018, which reflected ~19% year-over-year growth and ~12% sequential growth. Jazz Pharmaceuticals anticipates Xyrem’s net revenues in fiscal 2018 to be in the range of $1.87 million and $1.91 million.
On August 7, Jazz Pharmaceuticals (JAZZ) released its second-quarter 2018 financial results. Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.
On August 7, Mallinckrodt (MNK) reported revenues of ~$631.7 million for the second quarter, which is ~5.3% growth YoY (year-over-year) on a reported basis and 5.0% on a constant currency basis. The company reported non-GAAP EPS of $1.78, which is a rise of 30.9% YoY. The company beat Wall Street analysts’ revenue and non-GAAP EPS estimates for the second quarter by $11.31 million and $0.30, respectively.
Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q2. However, sales of its newest drug, Vyxeos disappoint. Stock down 7% in after-hours trading.
On a per-share basis, the Dublin-based company said it had net income of $1.50. Earnings, adjusted for one-time gains and costs, were $3.49 per share. The results exceeded Wall Street expectations. The ...
Apple is easing after reaching the $1 trillion market-value milestone, yet remains a stock market leader and industry innovator. Tech stocks in software, hardware broke out.
Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Jazz Pharmaceuticals is the IBD Stock Of The Day as the pharmaceutical company approaches a buy point ahead of its second-quarter report next week. Shares are forming a flat base with a buy point at 184.10
In June, the FDA accepted Jazz Pharmaceuticals’ (JAZZ) supplemental new drug application (or sNDA) for the label expansion of Xyrem. Jazz Pharmaceuticals filed an sNDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric narcolepsy patients. Jazz Pharmaceuticals’ sNDA was supported by data from the Phase 2/3 EXPRESS trial, which was conducted on pediatric patients between seven and 17 years old with narcolepsy.
Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million in the first quarter, reflecting an ~18% YoY (year-over-year) rise. Xyrem and Vyxeos primarily pushed the company’s revenue growth in the quarter.
In June, Jazz Pharmaceuticals (JAZZ) entered into an agreement with TerSera Therapeutics to sell its rights associated with Prialt to TerSera. As per the terms of the agreement, TerSera will provide employment opportunities to the majority of the Jazz Pharmaceuticals’ employees associated with Prialt. Presently, Prialt is the only therapy approved by the FDA for the treatment of chronic pain in adult individuals in need of intrathecal therapy.